Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona

Video navigation menu

LDL-c in the pathophysiology of atherosclerosis 2:42
Once a fatty streak lesion is present, plaque inflammation develops and the plaque progresses 5:04
Cholesterol crystals characterize mature plaques 7:14
How did prevention trial interventions impact on the pathogenesis of atherosclerosis? 8:33
Potential mechanisms of how LDL-c lowering regresses and stabilizes plaques 11:56
Evidence accumulates: LDL is causal in ASCVD 13:30

Educational information

The educational objectives of the symposium were to:

Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management
Understand the implications of new ESC guidelines for lipid management

Disclosures

John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Funding

This symposum was supported by unrestricted educational grants provided by Amgen and Sanofi-Regeneron

Download abstract and key slides View and download slides

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.